Absence of MxA induction is related to a poor clinical response to interferon beta treatment in multiple sclerosis patients-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Absence of MxA induction is related to a poor clinical response to interferon beta treatment in multiple sclerosis patients

Published:2016-02-12 Issue:4 Volume:263 Page:722-729
ISSN:0340-5354
Container-title:Journal of Neurology
language:en
Short-container-title:J Neurol

Author:

Matas Elisabet,Bau Laura,Martínez-Iniesta María,Romero-Pinel Lucía,Mañé-Martínez Maria Alba,Martínez-Yélamos Sergio

Funder

Convenio de Investigación. Dep. de Salut. Generalitat de Catalunya

Publisher

Springer Science and Business Media LLC

Subject

Neurology (clinical),Neurology

Link

http://link.springer.com/content/pdf/10.1007/s00415-016-8053-z.pdf

Reference35 articles.

1. The IFNB Multiple Sclerosis Study Group (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo controlled trial. Neurology 43:655–661

2. Jacobs LD, Cookfair DL, Rudick RA et al (1996) Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 39:285–294

3. PRIMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group (1998) Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 352:1498–1504

4. PRISMS (Prevention of Relapses and Disability by Interferon-β-1a Subcutaneously in Multiple Sclerosis) Study Group and the University of British Columbia MS/MRI Analysis Group (2001) PRISMS-4: long-term efficacy of interferon-β-1a in relapsing MS. Neurology 56:1628–1636

5. Río J, Nos C, Tintoré M et al (2002) Assessment of different treatment failure criteria in a cohort of relapsing-remitting multiple sclerosis patients treated with interferon beta: implications for clinical trials. Ann Neurol 52:400–406

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Novel peripheral blood mononuclear cell mRNA signature for IFN-beta therapy responsiveness prediction in multiple sclerosis;Autoimmunity;2024-03-28

2. Interferon Signature’s Members, a Novel Altered Correlation upon Interferon-β Treatment in Multiple Sclerosis Patients;Current Molecular Medicine;2023-10-12

3. Interferon beta-1a sc at 25 years: a mainstay in the treatment of multiple sclerosis over the period of one generation;Expert Review of Clinical Immunology;2023-09-11

4. Evaluating the Utility of Proteomics for the Identification of Circulating Pharmacodynamic Biomarkers of IFNβ ‐1a Biologics;Clinical Pharmacology & Therapeutics;2022-11-19

5. A long-term follow-up study on biochemical and clinical biomarkers of response to interferon beta-1b treatment in relapsing-remitting multiple sclerosis;Advances in Clinical and Experimental Medicine;2020-06-05

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3